Capital World Investors Updates GILD Stake to 83.7M Shares

TL;DR

**Capital World Investors still holds a massive 83.7 million shares of GILD.**

AI Summary

Capital World Investors, a major institutional investor, has updated its holdings in Gilead Sciences, Inc. (GILD) as of December 29, 2023. The filing shows they beneficially own 83,698,215 shares of common stock, representing a significant stake. This matters to investors because large institutional ownership can signal confidence in the company's long-term prospects, potentially influencing stock stability and future performance.

Why It Matters

This filing indicates a major institutional investor's current position in Gilead Sciences, which can influence market perception and potentially provide a floor for the stock price.

Risk Assessment

Risk Level: low — This filing is an update on an existing institutional holding, not a new position or a significant divestment, indicating stability.

Analyst Insight

Investors should note that a major institutional investor like Capital World Investors maintains a substantial position in GILD, suggesting continued confidence. While not a new buy, it indicates stability in large-holder sentiment.

Key Numbers

• 83,698,215 — Shares Beneficially Owned (Represents the total number of Gilead Sciences common shares Capital World Investors has the power to dispose of.)
• 83,354,771 — Sole Voting Power Shares (Indicates the number of shares Capital World Investors can vote on its own.)
• 375558103 — CUSIP Number (Unique identifier for Gilead Sciences, Inc. Common Stock.)

Key Players & Entities

• Capital World Investors (company) — the reporting person and institutional investor
• Gilead Sciences, Inc. (company) — the subject company whose stock is being reported
• 83,698,215 (dollar_amount) — total shares beneficially owned by Capital World Investors
• December 29, 2023 (date) — the date of the event requiring this filing
• Delaware (company) — place of organization for Capital World Investors

FAQ

From the Filing

0001422848-24-000274.txt : 20240209 0001422848-24-000274.hdr.sgml : 20240209 20240209182128 ACCESSION NUMBER: 0001422848-24-000274 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20240209 DATE AS OF CHANGE: 20240209 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: GILEAD SCIENCES, INC. CENTRAL INDEX KEY: 0000882095 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 943047598 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-42340 FILM NUMBER: 24616848 BUSINESS ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 BUSINESS PHONE: 6505743000 MAIL ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 FORMER COMPANY: FORMER CONFORMED NAME: GILEAD SCIENCES INC DATE OF NAME CHANGE: 19930328 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Capital World Investors CENTRAL INDEX KEY: 0001422849 ORGANIZATION NAME: IRS NUMBER: 951411037 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 333 SOUTH HOPE STREET STREET 2: 55TH FLOOR CITY: LOS ANGELES STATE: CA ZIP: 90071 BUSINESS PHONE: 213-486-9200 MAIL ADDRESS: STREET 1: 333 SOUTH HOPE STREET STREET 2: 55TH FLOOR CITY: LOS ANGELES STATE: CA ZIP: 90071 SC 13G/A 1 SEC13G_Filing.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 ) * Gilead Sciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 375558103 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes.) CUSIP No. 375558103 1. NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Capital World Investors 95-1411037 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ] (b) [ ] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 83,354,771 6. SHARED VOTING POWER 0 7. SOLE DISPOSITIVE POWER 83,698,215 8. SHARED DISPOSITIVE POWER 0 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 83,698,215 Beneficial ownership disclaimed pursuant to Rule 13d-4 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 6.7% 12. TYPE OF REPORTING PERSON IA Item 1. (a) Name of Issuer Gilead Sciences, Inc. (b) Address of Issuer's Principal Executive Offices 333 Lakeside Drive, Foster City, CA 94404 Item 2. (a) Name of Person Filing Capital World Investors (b) Address of Principal Business Office or, if None, Residence 333 SOUTH HOPE STREET, 55TH FLOOR, LOS ANGELES, CALIFORNIA 90071 (c) Citizenship N/A (d) Title of Class of Securities Common Stock (e) CUSIP Number 375558103 Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a: (a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o). (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c). (c) [ ] Insuran